DOHA: Qatar Red Crescent Society (QRCS) has announced providing vital cancer drugs worth US$1mn to meet the needs of patients with cancer among internally displaced people (IDP) and local communities in northern Syria for five months.
In a statement, QRCS said that the project also involved the provision of early diagnosis and treatment equipment and capacity-building for 25 medical professionals at the centres for cancer in the target areas.
Implemented in Idlib by QRCS's representation office in Gaziantep, Turkiye, the project is estimated to serve 3,700 direct beneficiaries and 18,500 indirect beneficiaries.
According to the project's action plan, the medical supplies were stored at QRCS warehouses in northern Syria, and they include 46 types of expensive chemotherapy and immunotherapy drugs, as well as early diagnosis and treatment devices for 3,500 patients.
The statement said that this project will contribute to the early detection and treatment of cancer patients of all age groups, by providing modern diagnostic devices and therapeutic drugs, in addition to providing capacity-building for the medical professionals working on treating cancer patients, in coordination with partners and health directorates there.
Socio-economically, this project will make a real difference in the lives of many patients with cancer, by filling in the gap in supply chains for the centres of cancer, thus ensuring the continuity of life-saving specialized and free-of-charge medical services.
